Prognostic impact of lymphangiogenesis and lymphatic invasion (CD105 expression) in small cell lung carcinoma

Anticancer Research

Volumn 28, Issue 1 A, 2008, Pages 343-348

  Hardavella, Georgia ^a,c   Arkoumani, Evdokia ^a   Dalavanga, Yiotanna ^a   Galanis, Petros ^b   Agnantis, Niki J ^a   Constantopoulos, Stavros ^a   Stefanou, Dimitrios ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c NONE   (Greece)

Author keywords

CD105; Immunohistochemistry; Lymphangiogenesis; Prognosis; Small cell lung carcinoma

Indexed keywords

ENDOGLIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; LUNG SMALL CELL CANCER; LYMPHANGIOGENESIS; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

AGED; ANTIGENS, CD; CARCINOMA, SMALL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES;

EID: 40549106093     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Plate K: From angiogenesis to lymphangiogenesis. Nature Medicine 7(2): 151-152, 2001.
2. American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer Society; 2006.
3. Stefanou D, Batistatou A, Arkoumani E, Ntzani E and Agnantis NJ: Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small cell and non-small cell lung carcinomas. Histol Histopathol 19: 37-42, 2004.
4. Stefanou D, Goussia AC, Arkoumani E and Agnantis NJ: Expression of vascular endothelial growth factor and the adhesion molecule E-cadherin in non-small cell lung cancer. Anticancer Res 23(6C): 4715-4720, 2003.
5. Baillie R, Carlile J, Pendleton N and Schor AM: Prognostic value of vascularity and vascular endothelial growth factor expression in non small cell lung cancer. J Clin Pathol 54: 116-120, 2001.
6. Georgiou L, Minopoulos G, Lirantzopoulos N, Fiska-Demetriou A, Maltezos E and Sivridis E: Angiogenesis and p53 at the invading tumor edge: prognostic markers for colorectal cancer beyond stage. J Surg Res 131(1): 118-123, 2006.
7. Meunier-Carpentier S, Dales JP, Djemli A, Garcia S, Bonnier P, Andrac-Meyer L, Lavaut MN, Allasia C and Charpin C: Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. Int J Oncology 26: 977-984, 2005.
8. Kyzas PA, Stefanou D, Batistatou A and Agnantis NJ: Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 131(9): 624-630, 2005.
9. Kumar P, Wang JM and Bernabeu C: CD 105 and angiogenesis. J Pathol 178: 363-366, 1996.
10. Quackenbush EJ and Letarte M: Identification of several cell surface proteins of non-T, non-B acute lymphoblastic leukaemia by using monoclonal antibodies. J Immunol 141: 1925-1933, 1985.
11. Gougos A and Letarte M: Biochemical characterization of the 44G4 antigen from the HOON pre-B leukemic cell line. J Immunol 141: 1934-1940, 1988.
12. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES and Thorpe PE: Up-regulation of endoglin on vascular endothelial cells in human solid tumours: implications for diagnosis and therapy. Clin Cancer Res 1: 1623-1634, 1995.
13. Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J and Hunter RD: A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int. J. Cancer 54: 363-370, 1993.
14. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM and Bundred N: Breast carcinoma: vascular density determined usind CD105 antibody correlates with tumour prognosis. Cancer Res 59: 856-861, 1999.
15. Kyzas PA, Agnantis NJ and Stefanou D: Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma. Virchows Arch 448(6): 768-775, 2006.
16. Greene LF, Page DL, Fleming ID et al: AJCC Cancer Staging Handbook. Springer, 6th Edition, pp. 191-203, 2002.
17. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111(6): 1710-1717, 1997.
18. Brambilla E, Travis WD, Colby TV et al: The new World Health Organization classification of lung tumours. Eur Respir J 18: 1059-1068, 2001.
19. Kuroda H, Sakamoto G, Ohnisi K and Itoyama S: Clinical and pathologic features of invasive micropapillary carcinoma. Breast Cancer 11: 169-174, 2004.
20. Porter GJ: Patterns of metastatic breast carcinoma: influence of tumour histological grade. Clin Pathol 59: 1094-1098, 2004.
21. Dales JP, Garcia S, Carpentier S, Djemli A, Andrac L, Lavaut MN, Allasia C and Bonnier P: Tumour nenoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays. Clin Cancer Res 10(17): 5815-5819, 2004.
22. Dales JP, Garcia S, Andrac L, Carpentier S, Ramuz O, Lavaut MN, Allasia C, Bonnier P and Charpin C: Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome. Int J Oncol 24(5): 1197-1204, 2004.
23. Mineo TC, Ambrogi V, Baldi A, Rabitti C, Bollero P, Vincenzi B and Tonini G: Prognostic impact of VEGF, CD31, CD34 and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non small cell lung cancer. J Clin Path 57: 591-597, 2004
24. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Yamada T, Hanaoka N, Inui K and Wada H: Evaluation of angiogenesis in non-small cell lung cancer. Comparison between anti-CD34 and anti-CD105 antibody. Clin Cancer Res 7: 3410-3415, 2001.
25. Yu JX, Zhang XT, Liao YQ, Zhang QY Chen H, Lin M and Kumar S: Relationship between expression of CD105 and growth factors in malignant tumors of gastrointestinal tract and its significance. World J Gastroenterol 9(12): 2866-2869, 2003.
26. Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, O'Dwyer ST, Haboubi N and Kumar S: Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 88(9): 1424-1431, 2003.
27. Wikstrom P, Lissbrant IF, Stattin P, Egevad L and Bergh A: Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51(4): 268-275, 2002.
28. Ho JW, Poon RT, Sun CK, Xue WC and Fan ST: Clinicopathological and prognostic implications of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver. World J Gastroenterol 11(2): 176-181, 2005.